Overview

For teams commercializing a 98-gene lung cancer assay, the sixty-three targeted and thirty-six chemotherapy markers are only the beginning; regulatory fitness decides whether the report can actually inform care. The combined panel spans targeted-therapy and chemotherapy-associated markers in one next-generation sequencing assay. This article outlines the pathways and documentation that support a defensible, market-ready offering rather than a scientifically strong but unusable result. Resolving compliance early prevents costly rework once a testing service is already operating in the field, and it spares the commercial team the embarrassment of a launch blocked by a classification question raised too late.

In-Vitro Diagnostic Classification

NGS tests are typically regulated as in-vitro diagnostics, requiring confirmation that the intended use matches the market's classification rules. Some jurisdictions require notified-body review or local registration before a report can support treatment decisions. Clarify early whether the service is offered as a laboratory-developed test under local oversight or as a registered device, since the evidence bar and post-market obligations differ between the two routes.

Evidence, Labeling and Traceability

A compliant service maintains analytical and clinical validation for the reported genes and states the intended use clearly in its labeling. Records should trace each report from received sample through sequencing and interpretation to the signed result. This traceability protects both the provider and the treating clinician if a result is later queried, and it demonstrates control over the full testing lifecycle during inspection.

Data Governance and Cross-Border Supply

Genomic data carries privacy obligations; confirm how sequence and report data are stored, transferred, and deleted under applicable law. For cross-border supply, align contracts with the destination market's diagnostic rules and confirm that the report format meets local clinical documentation standards. Proactive compliance reduces the risk of rejected reports and interrupted service, which can be costly once volume is committed.

FAQ

Q: Is a 98-gene test a registered device everywhere? A: Not necessarily. It may be a laboratory-developed test under local oversight in some markets and a registered device in others; confirm the classification for each market.

Q: What validation evidence should providers keep? A: Analytical and clinical validation for the reported genes, plus full traceability from sample receipt to signed report.

Q: How are genomic data privacy risks managed? A: Through defined storage, transfer, and deletion controls that meet applicable data-protection law for the markets served.